

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, June 21, 2022
Alfresa Holdings Corporation

**Notice regarding Cancellation of Treasury Shares
(Cancellation of treasury shares pursuant to the provisions of Article 178 of the
Companies Act of Japan)**

Alfresa Holdings Corporation hereby announces that, at a meeting of its Board of Directors held on June 21, 2022, it resolved to cancel a portion of its treasury shares pursuant to Article 178 of the Companies Act of Japan, as outlined below.

- | | |
|------------------------------------|--|
| 1. Type of shares to be canceled | Common stock |
| 2. Number of shares to be canceled | 32,177,600 shares
(13.7% of the number of outstanding shares before cancellation) |
| 3. Date of cancellation | July 15, 2022 |

(Reference)

- | | |
|---|--------------------|
| Number of outstanding shares after cancellation | 202,840,000 shares |
| Number of treasury shares before cancellation* | 32,648,047 shares |

* As of the end of March 2022. It includes the Company's 153,700 shares held by the Board Incentive Plan (BIP) trust account for officers' compensation.

About Alfresa Group

The Alfresa Group is a leader in Japanese healthcare industry, which is dedicated to make its corporate philosophy "we create and deliver a fresh life for all" come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported its consolidated revenue of ¥2.5 trillion (US\$20 billion) for the fiscal year ended March 31, 2022. For more information, please see: <https://www.alfresa.com/eng/>